Ozempic vs Zepbound: Cross-Category GLP-1 Comparison

Different active ingredients, different FDA indications — but both are GLP-1 medications people compare when exploring treatment options.

Take the Free Quiz

Free consultation · No commitment · Results in weeks

Patient
Patient
Patient
Patient
Patient
4.9/5

From 2,000+ patients · Ozempic vs Zepbound is already seeing results

Licensed Providers
FDA-Approved Medications
Free Shipping
HIPAA Compliant
Updated March 2026Medically reviewed by licensed providers

Ozempic vs Zepbound: both are FDA-approved GLP-1 medications for weight loss. Ozempic (semaglutide) and Zepbound (tirzepatide) differ in mechanism and clinical efficacy. Weight Method offers both from $297/month with virtual consultations and licensed providers.

Overview

Ozempic (semaglutide, Novo Nordisk) and Zepbound (tirzepatide, Eli Lilly) represent different corners of the GLP-1 landscape. Ozempic was FDA-approved in 2017 for type 2 diabetes, while Zepbound was approved in 2023 specifically for chronic weight management. They also use different molecules: Ozempic targets only GLP-1 receptors, while Zepbound activates both GLP-1 and GIP receptors. This comparison often arises for patients with diabetes who are also seeking significant weight loss.

Key Fact

Ozempic (semaglutide, 2017) is approved for type 2 diabetes with 10-15% weight loss. Zepbound (tirzepatide, 2023) is approved for weight management with 20-25% weight loss. Different molecules, different indications — Zepbound's dual GIP/GLP-1 mechanism roughly doubles the weight reduction.

Source: FDA prescribing information; SUSTAIN trials; SURMOUNT-1 (NEJM 2022)

Ozempic

ManufacturerNovo Nordisk
Active Ingredientsemaglutide
FDA IndicationType 2 diabetes
FDA Approval2017
FormulationInjectable pen
FrequencyOnce weekly
Available Doses0.25mg, 0.5mg, 1mg, 2mg
Avg. Weight Loss10-15%
Our Price$297/mo

Zepbound

ManufacturerEli Lilly
Active Ingredienttirzepatide
FDA IndicationChronic weight management
FDA Approval2023
FormulationInjectable pen
FrequencyOnce weekly
Available Doses2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg
Avg. Weight Loss20-25%
Our Price$349/mo

Key Differences

The gap between these medications is substantial. Zepbound produces 20-25% average weight loss in obesity trials — roughly double Ozempic's 10-15% in diabetes trials. However, Ozempic has the longer clinical track record (8+ years on market) and established cardiovascular outcome data. Their FDA-approved purposes don't overlap: Ozempic for blood sugar management, Zepbound for weight reduction. Pricing through Weight Method reflects the different molecules — $297/mo for semaglutide and $349/mo for tirzepatide.

Verdict

If type 2 diabetes is your primary condition, Ozempic is the established, FDA-approved choice with meaningful weight loss as a secondary benefit. If weight loss is your primary goal and you qualify based on BMI criteria, Zepbound delivers the most aggressive weight reduction results available. Your Weight Method provider can evaluate both options during your consultation.

Ready to Get Started?

Answer a few quick questions to see if you qualify for GLP-1 medication.

Check Eligibility

Your Treatment Options

Clinically proven GLP-1 medications at transparent prices

Starting at$297/mo
Semaglutide
Most PopularIn Stock

Semaglutide

Same active ingredient as Ozempic® & Wegovy®. Proven to reduce body weight by up to 15%.

  • Weekly injection
  • Gradual dose increase
  • Provider monitoring
  • Free shipping
Check Eligibility
Tirzepatide
In Stock

Tirzepatide

Same active ingredient as Mounjaro® & Zepbound®. Dual-action GLP-1/GIP for enhanced results.

  • Weekly injection
  • Dual hormone action
  • Provider monitoring
  • Free shipping
Check Eligibility

Frequently Asked Questions

Yes, significantly. Zepbound's clinical trials show 20-25% average body weight loss, compared to 10-15% with Ozempic. Zepbound's dual GIP/GLP-1 mechanism and its specific approval for weight management (versus Ozempic's diabetes indication) contribute to this difference.

No, you should not take both simultaneously. They are both GLP-1 receptor agonists, and combining them would increase the risk of serious side effects without proven additional benefit. Your provider will prescribe one or the other based on your health profile and treatment goals.

Both have similar gastrointestinal side effects — nausea, vomiting, diarrhea, and constipation are the most common. Some data suggests tirzepatide (Zepbound) may produce slightly less nausea at equivalent efficacy levels, but individual responses vary. Side effects for both tend to improve after the initial dose escalation period.

Consider switching if your primary goal is weight loss and you're not achieving your target on Ozempic, or if your provider recommends the dual-action approach. The switch requires medical supervision with a new dose titration schedule. Discuss your goals and options during an Weight Method consultation.

They belong to the same drug class (GLP-1 receptor agonists) but are different molecules. Semaglutide (Ozempic) activates only GLP-1 receptors, while tirzepatide (Zepbound) activates both GLP-1 and GIP receptors. This dual mechanism is why tirzepatide generally produces greater weight loss and glucose reduction.

Ready to Get Started?

Take our 2-minute quiz to see if you qualify for GLP-1 treatment.

Start Quiz

Free consultation. No commitment.

Related Brand Pages

Ozempic HubOzempic Side EffectsOzempic ResultsOzempic DosingZepbound HubZepbound Side EffectsZepbound ResultsZepbound Dosing

More Comparisons

Ozempic vs WegovyMounjaro vs ZepboundRybelsus vs Oral-wegovyOzempic vs MounjaroWegovy vs ZepboundWegovy vs Mounjaro